replicates.
were tested to downregulate NFATC2; si7 and si8 were selected for functional studies. OSCC3-GALR2 cells exhibit reduced (c) proliferation and (d) invasion when NFATC2 is downregulated using siRNA.
(For (c) and (d) *P < 0.05 two sample t-test; data represent mean + SD). (e) shRNAs were tested to use for constitutive downregulation of NFATC2 in UM-SCC-1-GALR2 and OSCC3-GALR2; sh2 was selected. (f) OSCC3-GALR2-shNFATc2-2 (sh2) cells exhibit reduced proliferation whereas OSCC3-GALR2-shNFATc2-1 (sh1) with no downregulation of NFATc2 exhibited the same proliferation as OSCC3-GALR2. (*P < 0.05 two sample t-test; data represent mean + SD). 
Supplementary Tables
Supplementary Supplementary Table 3 : Summary information about studies for Supplementary Fig. 1a . comparing COX2 expression in normal and cancerous tissues. The meta-analysis was conducted as a one sample t-test comparing the proportion of studies that were statistically significant at the 0.05 level. The P-value from the meta-analysis was 0.0001, sufficiently extreme to reject the null hypothesis that there was no relationship between COX2 expression and tissue cancer status. Table 6 : siRNA target sequences for NFATC2 PTGS2 (COX2), Galanin (GAL) and GALR2 (Dharmacon) used in this study.
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